AD80 | MedChemExpress (MCE)

AD80 产品活性：AD80 是多种激酶的抑制剂，抑制 RET，RAF，SRC 和 S6K 活性，但对 mTOR 的活性明显减弱。 产品来源： https://www.medchemexpress.cn/AD80.html 研究领域：MAPK/ERK Pathway | Protein Tyrosine Kinase/RTK 作用靶点：Raf | Src | Ribosomal S6 Kinase (RSK) | RET In Vitro: AD80 is a polypharmacological agent with an optimal balance of activity against Ret, Raf, Src, Tor and S6K that show high efficacy with very low toxicity. AD80 and AD81 inhibits RET, RAF, SRC and S6K, with greatly reduced mTOR activity relative to AD57 and AD58.AD80 is optimal for Ras–Erk pathway inhibition. AD80 inhibits proliferation of MZ-CRC-1 and TT thyroid cancer cells in culture, probably through the induction of apoptosis. Immunoblot analysis demonstrates potent downregulation of phosphorylated Ret and several downstream biomarkers within these cells. AD80 coordinately inhibits S6K1 together with the TAM family tyrosine kinase AXL.AD80 avoides S6K1 phosphorylation and mTOR co-association, resulting in durable suppression of S6K1-induced signaling and protein synthesis. In Vivo: Oral administration of either AD80 or AD81 results in a notable 70-90% of animals developing to adulthood in Drosophila ptc>dRetMEN2Bmodel, a considerable improvement over the efficacy observed with AD57. AD80 also promotes enhanced tumour growth inhibition and reduces body-weight modulation relative to vandetanib in a mouse xenograft model. AD80 rescues 50% of mice transplanted with PTEN-deficient leukemia cells. 相关产品：Covalent Screening Library Plus | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Protein Tyrosine Kinase Compound Library | Anti-Cancer Compound Library | Covalent Screening Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Ferroptosis Compound Library | Glutamine Metabolism Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Heterocyclic Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Serine/Threonine Kinase Inhibitor Library | Anti-Hematopathy Compound Library | Multi-Target Compound Library | Bioactive Compound Library Max | Sorafenib | Dasatinib | Lenvatinib | Dabrafenib | Vemurafenib | Regorafenib | Ponatinib | Doramapimod | Encorafenib | Saracatinib | PP2 | Bosutinib | Selpercatinib | SB-590885 | Pralsetinib | BI-D1870 | PLX-4720 | Rebastinib | Avutometinib | PF-4708671 | Carnosol | WH-4-023 | Masitinib | LY3009120 | Belvarafenib | GDC-0879 | Tovorafenib 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。

AD80 | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供，如您想了解更多关于AD80 | MedChemExpress (MCE)报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途